Corpus Intelligence IC Memo — MYMICHIGAN MEDICAL CENTER-CLARE 2026-04-26 13:01 UTC
IC Memo — MYMICHIGAN MEDICAL CENTER-CLARE
Investment Committee Memorandum | MI | 49 beds | Grade C | EBITDA uplift $5.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MYMICHIGAN MEDICAL CENTER-CLARE

CCN 230180 | nan, MI | 49 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MYMICHIGAN MEDICAL CENTER-CLARE is a 49-bed suburban community hospital in nan, MI with $67.7M in net patient revenue and a 0.3% operating margin. The hospital serves a payer mix of 31.7% Medicare, 2.6% Medicaid, and 65.8% commercial.

Thesis: Turnaround. Our ML models identify $5.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.3% to 7.7% (+736bps).

Net Revenue HCRIS$67.7M
Current EBITDA COMPUTED$233K
Operating Margin COMPUTED0.3%
Occupancy HCRIS12.9%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS32.4%
Distress Probability ML56.3%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
72
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of 0.3% places it above the state median. Among 72 size-comparable peers (24-98 beds), the median margin is -3.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (24-98), prioritizing same-state peers. 72 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MYMICHIGAN MEDICAL CENTER-CLAR (Target)MI49$67.7M0.3%
TRINITY HEALTH LIVINGSTONMI42$200.4M15.2%
CHELSEA HOSPITALMI79$187.8M-1.1%
BEAUMONT HEALTH WAYNEMI97$180.7M-3.6%
OAKLAWN HOSPITALMI78$156.6M-12.4%
MYMICHIGAN MEDICAL CENTER ALMAMI49$142.2M-5.9%
SPECTRUM HEALTH UNITED MEMORIAMI45$129.4M9.7%
MCLAREN LAPEER REGIONMI92$127.1M-1.5%
DICKINSON COUNTY HEALTHCARE SYMI49$126.3M-4.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.4M+210bp18mo
Cost to Collect4.5%2.5%$1.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$824K+122bp9mo
Clean Claim Rate88.0%96.0%$43K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.4M
Cost to Collect
$1.4M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$824K
Clean Claim Rate
$43K
Total EBITDA Uplift$5.0M
Current EBITDA$233K
+ RCM Uplift+$5.0M
Pro Forma EBITDA$5.2M
Current Margin0.3%
Pro Forma Margin7.7%
WC Released (1x)$2.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$359K$51.4M143.10x169.8%
Base (11x exit)10.0x11.0x$359K$56.6M157.73x175.2%
Bull Case9.0x11.0x$323K$73.2M226.52x195.8%
Bull (12x exit)9.0x12.0x$323K$79.9M247.40x201.1%
Bear Case11.0x10.0x$395K$26.3M66.70x131.6%
Bear (11x exit)11.0x11.0x$395K$29.1M73.69x136.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 12.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 56.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 72 hospitals with 24-98 beds
  • Same-state prioritization (n=73)
  • Comp margins: P25=-12.4% / P50=-3.5% / P75=7.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.